Cross-sectional

Follow-up of positive cases of lymphatic filariasis after Transmission Assessment Survey (TAS) 2 and TAS 3 in Burkina Faso

Identify the sampling strategy for tracking positive cases after TAS 2 and TAS 3 that optimizes the chances of correctly identifying evidence of active transmission, while saving program resources

Countries: Burkina Faso

Understanding areas of increased trachoma risk (hotspots) through the implementation of a post validation trachoma surveillance strategy

To determine if there is evidence of on-going or recent transmission in the “hotspot” communities of increased risk two years after they were identified during the pre-validation surveys (clinical, antibody and infection data).

Countries: Ghana
Diseases: Trachoma

Is Preventive Chemotherapy for NTDs Really “Pro-Poor?”: Insights from the Demographic and Health Surveys

To use DHS data from 40 countries to examine the extent to which deworming of children 1-4 years is associated with: 1) a range of individual- and family-related socioeconomic indicators, including wealth quintile and maternal education; and 2) access to health systems that could provide opportunities for deworming, independent of family-level socioeconomic status.

Countries:

Improving Mass Drug Administration After Transmission Assessment Survey Failure: Results from a Mixed Methods Study

  • What factors are associated with the availability, accessibility, and acceptability of MDA?
  • What is the impact of an adapted and tailored intervention package on effective coverage?
Countries: Ghana | Burkina Faso

Addressing the Mental Health of Persons Living with Lymphatic Filariasis in Léogâne, Haiti: Effectiveness of a Chronic Disease Self-Management Program

Intervention: The primary aim of this project is to determine if the introduction of a Chronic Disease Self-Management curriculum into existing Hope Clubs in Léogâne, Haiti will result in improvements in symptoms of depression, self-rated health, chronic disease self-efficacy, social support, and disability.

Formative: What are the barriers that prevent people with LF from participating in Hope Clubs?

Countries: Haiti

Coverage Evaluation Survey and Supervisor's Coverage Tool Implementation in Kenya for Triple Drug Therapy

Coverage Evaluation Survey

Is coverage, or a combination of coverage and systematic non-compliance, more effective than a diagnostic tool at predicting when it is safe to stop triple drug therapy?

Supervisor's Coverage Tool

Is the use of the SCT during IDA feasible to implement at the sub-county scale and does it lead to increased coverage?

Countries: Kenya

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Egypt

What is the indicator(s) and accompanying monitoring and evaluation (M&E) strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Egypt

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Kenya

  • What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of lymphatic filariasis has been reduced so that triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) can be stopped with little risk of resurgence of transmission?
  • Can the use of a tailored social mobilization package be used to strengthen community and health system participation and achieve >80% coverage for IDA in Kenya?
Countries: Kenya

Processing Ov16 ELISA for Oncho Elimination Mapping

Would the same programmatic decisions for Oncho Elimination Mapping be made based off of the Ov16 rapid diagnostic test results as compared to the Ov16 SD ELISA results?

Countries: Kenya | Malawi | Burundi
Diseases: Onchocerciasis

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Samoa

  • What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of lymphatic filariasis (LF) has been reduced so that triple drug therapy with ivermectin, diethylcarbamazine, and albendazoe (IDA) can be stopped with little risk of resurgence of transmission?
  • To develop an M&E strategy that enables Samoa’s LF elimination program to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission
  • What is the effectiveness of appropriately dosed IDA in clearing Mf from Mf positive people who (i) reported taking IDA in August 2018, and (ii) did not report recently taking IDA?

 

Countries: Samoa

Pages